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differences to be much higher than median differences.
Regression analysis explained about 40% of the cost 
variance and indicated no signiﬁcant total cost differences
between therapies. Clinically evaluable sample results
were qualitatively similar to the ITT sample. CONCLU-
SION: Substantial variation in hospital costs in this 
moderately large multinational Phase-3 trial does not
allow deﬁnitive conclusions regarding whether the length
of stay differences seen earlier result in total treatment
cost differences. In future research, combining data with
other similar trials may allow for more precise point esti-
mates of cost differences.
PIN12
PHARMACOECONOMIC ANALYSIS OF ACUTE
EXACERBATION OF CHRONIC BRONCHITIS
TREATMENT WITH TELITHROMYCIN OR
CEFUROXIME-AXETIL
Rubio-Terrés C1, Cots JM2, Domínguez-Gil A3, Herreras A1,
Sánchez Gascón F4, Chang J5,Trilla A6
1Aventis Pharma S.A, Madrid, Spain; 2Sociedad Catalana de
Medicina Familiar y Comunitaria-SCMFIC, Barcelona,
Spain; 3Hospital Universitario, Salamanca, Spain; 4Hospital
Virgen de la Arrixaca, (El Palmar) Murcia, Spain; 5Aventis
Pharma USA, Bridgewater, NJ, USA; 6Hospital Clinic,
Barcelona, Spain
OBJECTIVE: A pharmacoeconomic analysis was carried
out comparing the efﬁciency of two treatment options 
for acute exacerbation of chronic bronchitis (AECB):
Telithromycin and Cefuroxime-axetil. METHODS:
Retrospective analysis using a decision tree model. The
efﬁcacy of the 2 treatment options was estimated from 
a randomised, double-blind clinical trial, in which 
800mg/day (5 days) of Telithromycin was compared to
1,000mg/day (10 days) of Cefuroxime-axetil in patients
with AECB (140 and 142 respectively). The utilisation 
of resources was estimated from the clinical trial and
Spanish sources, and the unit costs from a Spanish health
costs database. Costs were evaluated for the acquisition
of antibiotic treatments, change of antibiotic due to 
therapeutic failure, hospital admissions, adverse reactions
treatment, primary care visits, tests and indirect costs
(working days lost). The model was validated by a panel
of Spanish clinical experts. RESULTS: As the clinical trial
was designed to show equivalence, there were no signiﬁ-
cant differences in efﬁcacy between the treatment 
options (clinical cure rate 86.4% and 83.1% respec-
tively), and a cost minimisation analysis was performed.
In the base case, the average cost of the disease per patient
was €174.83 with Telithromycin and €194.68 with
Cefuroxime-axetil (a difference of €19.85). The results
were stable in the sensitivity analysis, with differences
favourable to Telithromycin ranging between €18.04 and
€22.25. CONCLUSIONS: Telithromycin results in a cost
saving of up to €22 per patient with AECB compared to
Cefuroxime-axetil.
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OBJECTIVES: Clinical trials of antiretroviral (ARV) 
regimens are too short to allow a long-term assessment
of economic and quality of life differences for competing
regimens. However, surrogate marker data from ARV
trials used in a long-term mathematical model that incor-
porates epidemiologic and economic data, and current
treatment patterns, can be used to estimate long-term
costs and outcome differences. This study compares long-
term health outcomes and cost effectiveness of LVP/r vs.
NFV regimens in treatment-naïve patients. METHODS:
We developed a new generation three-compartment
Markov model with a combination of viral load and CD4
count as surrogate markers compared to the previous 
generation model using only CD4 count as a surrogate
marker. The model applied epidemiologic data from
5,000 patients on HAART therapy, cost data from 2,000
U.S. Medicaid patients, and quality of life data from
21,000 HIV-patient responses to the EQ5D. The model’s
predictive ability was tested against published HAART
study data, and on data from 1,456 HIV U.S. patients in
70 primary care practices. Into this validated model we
inserted the study VL and CD4 count data (ITT missing
= fail) from the 48-week analysis of the ABT-M98-863
clinical trial. RESULTS: The model estimated a $4,011
per patient cost savings in favor of the LVP/r regimen,
when budget impacts were compared over the ﬁrst 5
years. The incremental cost effectiveness ratio was
$3,423/QALY for LVP/r vs. NFV, and an improvement in
median survival of 24 QALYs for a cohort of 100 patients
was found. This cost effectiveness ratio is comparable to
values for generic blood pressure control medications.
The results were robust under sensitivity analysis. CON-
CLUSIONS: Under the model assumptions, use of LVP/r
in the ﬁrst ARV regimen, as compared to NFV, leads to
cost savings over the ﬁrst 5 years of therapy, and appears
to be cost effective over the patients lifetime.
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OBJECTIVES: To evaluate the cost-consequence of LVP/r
compared with NFV in treating antiretroviral (ARV)
naïve HIV patients. METHODS: A decision tree model
was developed based on the Department of Health and
Human Services (DHHS) guidelines and the survey of
HIV treating physicians. The model was used to reana-
lyze the ABT-M98-863 pivotal clinical trial data submit-
ted to FDA/EMEA, a randomized phase III study of LVP/r
vs. NFV plus d4T/3TC in 653 ARV naïve HIV patients.
Therapeutic failure was deﬁned as 2 successive (4 weeks
apart) viral loads (VL) >400 copies/ml. In the model,
therapeutic responders continued with their initial treat-
ment, while failures received drug resistance tests and
additional monitoring. Failures who developed drug
resistance switched to a 2PIs + 2NRTIs regimen, while
others stayed in the PI + 2NRTIs regimen class. A
maximum of 1 therapy switch was allowed. Failures were
at risk for AIDS events determined by CD4 count and VL.
Cost analysis in 2002 U.S. dollars was performed from a
third party payer’s perspective. One-way sensitivity analy-
sis tested the robustness of the assumptions. RESULTS:
The model showed that after 60 weeks of therapy, com-
pared to NFV, 22.1% more patients who started on LVP/r
remained as responders, yielding a net savings of
$1,454.14 per patient. Reduced treatment costs for
therapy failures and AIDS events were the main contri-
butions to the net savings. In sensitivity analysis, when
the VL threshold for therapeutic failure was set at 50,
1,000, or 5,000 copies/ml, cost savings remained at
$1,520.15, $1,233.52, and $1,062.26, respectively. When
the regimen for all failures was changed to 2PI + 2NRTIs,
PI + NNRTI + 2NRTIs, or PI + 2NRTIs, the estimated
savings changed to $2,704.38, $1,928.46, and $838.35,
respectively. CONCLUSIONS: The results suggest that if
treatment guidelines are applied in the management of
ARV naïve HIV patients, LVP/r may reduce the number
of patients switching regimens and consequently may
decrease total costs when compared with NFV.
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OBJECTIVE: The present study was carried out to 
evaluate the economic burden of chronic hepatitis B
(CHB) and its complications, and to evaluate the clinical
and economic beneﬁts of treatment of CHB patients with
lamivudine for one year in Shanghai, China. METHODS:
The components of the economic burden of disease
included direct medical costs, non-medical costs and 
indirect work related costs per patient per year in CHB
patients (n = 634), those who had progressed to com-
pensated hepatocirrhosis (n = 294), decompensated hepa-
tocirrhosis (n = 231) and hepatocellular carcinoma (n =
236), respectively. The direct medical costs per patient per
year were calculated according to the mean expenses and
utilisation rate for each outpatient visit and hospitalisa-
tion. The direct non-medical costs were estimated based
on expenses for nutrition products and transportation.
Mean indirect costs were calculated using average time
lost from work in one year. Clinical and economic 
beneﬁts of CHB treatment with lamivudine were esti-
mated using cost data from the burden of illness study in
Shanghai and seroconversion rate data in Asian patients
and cirrhosis progression rates from lamivudine clinical
trials. RESULTS: Treatment of patients with ALT >
2xULN with lamivudine for 1 year is estimated to result
in net total cost savings of US$51 per patient. CON-
CLUSION: Chronic hepatitis B infection not only com-
promises the patient’s normal daily activities, but also
imposes a signiﬁcant economic burden on patients and
their families. By reducing the rate of progression to cir-
rhosis, treatment of CHB patients with lamivudine for
one year can result in overall net cost savings.
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OBJECTIVES: To evaluate health outcomes and costs to
the health care payer of treating inﬂuenza in an at-risk
population with anti-virals (oseltamivir). METHODS:
Based on clinical trial data and data from the literature a
microsimulation model incorporating ﬁrst- and second-
order Monte Carlo simulation was developed. The under-
lying clinical pathway predicts morbidity and mortality
due to inﬂuenza and its speciﬁed complications. Health
outcomes (QALYs, days to return to normal activity) and
costs were estimated for events in the model. The model
compares various scenarios, which are deﬁned by alter-
native treatment schemes within deﬁned populations and
other parameters. Robustness of the results is tested 
by probabilistic and univariate sensitivity analysis. The
model is used to simulate the results for an at-risk popu-
lation in the UK comparing Oseltamivir with usual care.
RESULTS: Treatment with Oseltamivir within 48 hours
results in reduced morbidity, which translates into faster
recovery and faster return to normal activities (by 5.28
days). Lower morbidity and mortality make this a cost-
effective intervention from a health care payer perspec-
tive with Oseltamivir being dominant compared to usual
care in both cost-effectiveness and cost-utility analysis.
CONCLUSION: Treatment with Oseltamivir is effective
